PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY
In the last decade, molecularly-targeted therapy is the most intensively developing treatment modalities in oncology. The main targets for this therapy are many elements of apoptosis signaling pathways and cell cycle regulation, the damage of which is associated with a malignant growth. One of the a...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/32 |
| _version_ | 1797875948242075648 |
|---|---|
| author | P. A. Gervas N. V. Litviakov N. O. Popova A. Yu. Dobrodeev A. S. Tarasova E. L. Yumov F. G. Ivanova O. V. Cheremisina S. G. Afanasyev V. E. Goldberg N. V. Cherdyntseva |
| author_facet | P. A. Gervas N. V. Litviakov N. O. Popova A. Yu. Dobrodeev A. S. Tarasova E. L. Yumov F. G. Ivanova O. V. Cheremisina S. G. Afanasyev V. E. Goldberg N. V. Cherdyntseva |
| author_sort | P. A. Gervas |
| collection | DOAJ |
| description | In the last decade, molecularly-targeted therapy is the most intensively developing treatment modalities in oncology. The main targets for this therapy are many elements of apoptosis signaling pathways and cell cycle regulation, the damage of which is associated with a malignant growth. One of the available molecular targets is the epidermal growth factor receptor (EGFR), which activation occurs in lung cancer, colorectal cancer, squamous cell carcinoma of the head and neck , breast cancer, melanomas, etc. To block oncogenic EGFR signaling, target drug as small molecule tyrosine kinase inhibitors, peptide associated cytotoxins and antiEGFR monoclonal antibodies were created. However, there are a number of studies (FLEX, SATURN, INTEREST, IPASS), where the expected and observed clinical cure rates of target drugs are not the same, including primary goal - increasing time to tumor progression. As the cause of inconsistency of treatment results may be lack the selection of patients with the additional molecular damages (mutations or genetic polymorphisms), providing the sensitivity and /or resistance to therapeutic agent. The most important reason for discrepancy between the real and the expected treatment effect of target drugs is the phenomenon of intratumoral heterogeneity, that is manifested as coexist of cells with different biological properties, due to genetic, epigenetic, phenotypic peculiarities of tumor clones within the tumor. Search for new driver targets and the creation of drugs directed against them, development of multitarget approach are perspective to improve the effectiveness of targeted therapy. In addition, it is important to use molecular testing to monitor the treatment efficacy, because therapy can drive the tumor clonal evolution, leading to the emergence of resistant cell clones. |
| first_indexed | 2024-04-10T01:55:35Z |
| format | Article |
| id | doaj.art-a42cd8b6f05f4a57893a9014cc834738 |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2024-04-10T01:55:35Z |
| publishDate | 2016-02-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-a42cd8b6f05f4a57893a9014cc8347382023-03-13T09:05:46ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-02-0102465532PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPYP. A. Gervas0N. V. Litviakov1N. O. Popova2A. Yu. Dobrodeev3A. S. Tarasova4E. L. Yumov5F. G. Ivanova6O. V. Cheremisina7S. G. Afanasyev8V. E. Goldberg9N. V. Cherdyntseva10ФГБУ «НИИ онкологии» СО РАМН, г. ТомскФГБУ «НИИ онкологии» СО РАМН, г. Томск Томский государственный университет, г. ТомскФГБУ «НИИ онкологии» СО РАМН, г. ТомскФГБУ «НИИ онкологии» СО РАМН, г. ТомскФГБУ «НИИ онкологии» СО РАМН, г. ТомскФГБУ «НИИ онкологии» СО РАМН, г. ТомскГБУ РС(Я) «Якутский республиканский онкологический диспансер», г. ЯкутскФГБУ «НИИ онкологии» СО РАМН, г. ТомскФГБУ «НИИ онкологии» СО РАМН, г. ТомскФГБУ «НИИ онкологии» СО РАМН, г. ТомскФГБУ «НИИ онкологии» СО РАМН, г. Томск ГБОУ ВПО «Сибирский государственный медицинский университет» Минздрава РФ, г. Томск Томский государственный университет, г. Томск4In the last decade, molecularly-targeted therapy is the most intensively developing treatment modalities in oncology. The main targets for this therapy are many elements of apoptosis signaling pathways and cell cycle regulation, the damage of which is associated with a malignant growth. One of the available molecular targets is the epidermal growth factor receptor (EGFR), which activation occurs in lung cancer, colorectal cancer, squamous cell carcinoma of the head and neck , breast cancer, melanomas, etc. To block oncogenic EGFR signaling, target drug as small molecule tyrosine kinase inhibitors, peptide associated cytotoxins and antiEGFR monoclonal antibodies were created. However, there are a number of studies (FLEX, SATURN, INTEREST, IPASS), where the expected and observed clinical cure rates of target drugs are not the same, including primary goal - increasing time to tumor progression. As the cause of inconsistency of treatment results may be lack the selection of patients with the additional molecular damages (mutations or genetic polymorphisms), providing the sensitivity and /or resistance to therapeutic agent. The most important reason for discrepancy between the real and the expected treatment effect of target drugs is the phenomenon of intratumoral heterogeneity, that is manifested as coexist of cells with different biological properties, due to genetic, epigenetic, phenotypic peculiarities of tumor clones within the tumor. Search for new driver targets and the creation of drugs directed against them, development of multitarget approach are perspective to improve the effectiveness of targeted therapy. In addition, it is important to use molecular testing to monitor the treatment efficacy, because therapy can drive the tumor clonal evolution, leading to the emergence of resistant cell clones.https://www.siboncoj.ru/jour/article/view/32рецептор эпидермального фактора роста (egfr)молекулярное тестированиетаргетная терапиявнутриопухолевая гетерогенность |
| spellingShingle | P. A. Gervas N. V. Litviakov N. O. Popova A. Yu. Dobrodeev A. S. Tarasova E. L. Yumov F. G. Ivanova O. V. Cheremisina S. G. Afanasyev V. E. Goldberg N. V. Cherdyntseva PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY Сибирский онкологический журнал рецептор эпидермального фактора роста (egfr) молекулярное тестирование таргетная терапия внутриопухолевая гетерогенность |
| title | PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY |
| title_full | PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY |
| title_fullStr | PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY |
| title_full_unstemmed | PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY |
| title_short | PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY |
| title_sort | problem and perspective to improve molecular testing to choose appropriate target therapy |
| topic | рецептор эпидермального фактора роста (egfr) молекулярное тестирование таргетная терапия внутриопухолевая гетерогенность |
| url | https://www.siboncoj.ru/jour/article/view/32 |
| work_keys_str_mv | AT pagervas problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT nvlitviakov problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT nopopova problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT ayudobrodeev problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT astarasova problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT elyumov problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT fgivanova problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT ovcheremisina problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT sgafanasyev problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT vegoldberg problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy AT nvcherdyntseva problemandperspectivetoimprovemoleculartestingtochooseappropriatetargettherapy |